News Wire

A new study from University of Illinois at Chicago (UIC) researchers suggests that more than one-third of U.S. adults may be using prescription medications that have the potential to cause depression or increase the risk of suicide, and that because these medications are common and often have nothing…
Eli Lilly and AstraZeneca have announced that they will discontinue phase 3 trials of their BACE inhibitor lanabecestat for the treatment of Alzheimer's disease, according to a BioPharma Dive report. The AMARANTH study in early Alzheimer's disease, its extension study, as well as the DAYBREAK-ALZ trial…
The Trump administration is urging states to better use Medicaid for the delicate and difficult treatment of opioid-addicted and exposed infants, but did not offer any new outlets, according to a recent FierceHealthcare report. Congress, however, might be delivering on that front shortly. The Centers…
U.S. lawmakers fear the FDA is not doing enough to stop the flow of illegal drugs into the United States as the country works to combat the opioid epidemic, Reuters reports. Republican and Democratic members on the House Energy and Commerce Committee questioned whether the FDA’s criminal investigators…
The FDA has cleared a new auricular neurostimulation device (Drug Relief, DyAnsys, Inc.), to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics. The device is available for providers to prescribe for use during opioid detoxification. The wearable device sends electrical…
The FDA has approved Fulphila (pegfilgrastim-jmdb, Mylan GmbH) as the first biosimilar to Amgen’s Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting…
In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Scott Gottlieb, MD, wants to speed approval times for rivals to promising new first-to-market medicines, Reuters reports. The FDA chief has made a commitment to speeding up approvals of cheap generic medicines,…
New research indicates that millions of Americans may need to talk to their doctor about taking different prescriptions of aspirin, statins, and blood pressure medications, according to a study led by Stanford researchers. Sanjay Basu, MD, PhD, and his colleagues have come up with new calculations to…
A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. This patient received the treatment in a clinical trial led by Steven A. Rosenberg, MD, PhD,…
The FDA has approved an additional indication for tofacitinib (Xeljanz, Pfizer). The drug is approved for administration at 10 mg twice daily for at least eight weeks, followed by 5 mg twice daily or 10 mg twice daily, for the treatment of adult patients with moderately to severely active ulcerative…
The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital and the University of Toronto. Published in the Journal of the American College of Cardiology, the systematic review of existing…
The FDA is warning consumers that over-the-counter (OTC) teething products containing benzocaine pose a serious risk to infants and children. The agency has announced that OTC oral health products containing the pain reliever benzocaine for the temporary relief of sore gums due to teething in infants…
The FDA has approved pegvaliase-pqpz (Palynziq, BioMarin Pharmaceutical, Inc.) for adults with a rare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an inability to break down phenylalanine (Phe), an amino acid present in protein-containing foods and high-intensity…
U.S. health authorities are preparing to send an experimental Ebola treatment to the Democratic Republic of Congo for use in a clinical trial aimed at stemming an outbreak in the country that has spread to Mbandaka, a city of about 1.5 million people, Reuters reports. The trial would test the effectiveness…
Roche has announced that the Phase 3 IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). The combination of atezolizumab (Tecentriq, Roche) plus chemotherapy (carboplatin and albumin-bound paclitaxel; nab-paclitaxel [Abraxane, Celgene Corp.]) helped…

Pages